首页 | 本学科首页   官方微博 | 高级检索  
     


Dose,schedule, safety,and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
Authors:Gail J. Roboz MD  Hagop M. Kantarjian MD  Karen W. L. Yee MD  Patricia L. Kropf MD  Casey L. O'Connell MD  Elizabeth A. Griffiths MD  Wendy Stock MD  Naval G. Daver MD  Elias Jabbour MD  Ellen K. Ritchie MD  Katherine J. Walsh MD  David Rizzieri MD  Scott D. Lunin MD  Tania Curio MD  Woonbok Chung PhD  Yong Hao MD  James N. Lowder MD  Mohammad Azab MD  Jean‐Pierre J. Issa MD
Affiliation:1. Weill Cornell Medicine, NewYork‐Presbyterian Hospital, New York, New York;2. The University of Texas MD Anderson Cancer Center, Houston, Texas;3. Princess Margaret Cancer Centre, Toronto, Ontario, Canada;4. Fox Chase Cancer Center, Philadelphia, Pennsylvania;5. Keck School of Medicine, University of Southern California, Los Angeles, California;6. Roswell Park Cancer Institute, Buffalo, New York;7. University of Chicago, Chicago, Illinois;8. Ohio State University, Columbus, Ohio;9. Duke University Medical Center, Durham, North Carolina;10. Florida Cancer Specialist and Research Institute, Fort Myers, Florida;11. Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, Pennsylvania;12. Astex Pharmaceuticals, Pleasanton, California
Abstract:
Keywords:acute myeloid leukemia (AML)  guadecitabine  refractory  relapsed  SGI‐110
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号